Portfoliotracker

LENZ Therapeutics, Inc.

LENZ · NASDAQGS · Healthcare Biotechnology 9/100 E

3,820 $
▼ −0,310 (−7,51 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 13:39
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score9 / 100 Market cap120 mil. $ P/E– Forward P/E-3,3 P/S9,7 P/B0,6 EV/EBITDA– Dividend yield– FCF yield-106,40 % EPS-4,53 $ Net margin0,0 % Return on equity-72,7 % Beta1,81 Debt / equity0,00
52-week range 2,80 to 32,13
3-month average volume0,9 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

Employees
40
Country
United States
Fiscal year end
31. 12.
Data since
25. 6. 2021

Explore further

Similar companies MLYSLXEOELVNCGONTYRA

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account